Abstract
Pharmacological, angiographic, and biochemical studies indicate that platelets may play a key role in the initiation and evolution of atherosclerosis. They are also key to occlusive complication of the atherosclerotic plaque manifest clinically as unstable angina or myocardial infarction (Lewis et al. 1983; Cairns et al. 1985; Ambrose et al. 1986; Sherman et al. 1986; Fitzgerald et al. 1986; Theroux et al. 1987).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V (1986) Angiographic evolution of coronary artery morpholgy in unstable angina. J Am Coll Cardiol 7:474–478
Antiplatelet Trialists’ Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. Brit Med J 296:320–331
Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Brit Med J 308:81–106
Bellavance A, for the Ticlopidine Aspirin Stroke Study Group (1993) Efficacy of ticlopidine and aspirin for the prevention of reversible cerebrovascular ischemic events: the Ticlopidine Aspirin Stroke Study. Stroke 24:1452–1457
Bertele’ V, Cerletti C, Schippati A, di Minno G, de Gaetano G (1981) Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet i:1057–1058
Bertele’ V, de Gaetano G (1982) Potentiation by dazoxiben, a thromboxane synthetasse inhibitor, of platelet aggregation inhibition activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol 85:331–333
Bourassa MG, Schwartz L, Lesperance J, Eastwood C, Kazim F (1990) Prevention of acute complications after percutaneous transluminal coronary angioplasty. Thrombosis Res Suppl 12:51–58
Braden GA, Knapp HR, FitzGerald GA (1991) Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation 84:679–685
Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH (1985) Aspirin, Sufinpyrazone, or both in unstable angina. Results of a Canadian Multicenter Trial. N Engl J Med 313:1369–1375
Cannon CP, Novotny WF, McCabe CH, Tischler MD, Borzac S, Henry TD, Feldman R, Hamilton S, Rothman JM, Braunwald E, and the TIMI Investigators (1996) Evaluation of the oral glycoprotein IIb/IIIa antagonist Ro 48–3657 in patients post acute coronary syndromes: primary results of the TIMI 12 trial. Circulation 94:3231 A
CAPRIE Steering Committee (1996) A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339
Charo JF, Bekeart LS, Phillips DR (1987) Platelet glycoprotein IIb/IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem 262:9935–9938
Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US (1994) Inhibition of neointimal hyperplasia by blocking α v β 3 integrin with a small peptide antagonist Gpen GRGDSPCA. J Vase Surg 19:125–134
Clarke RJ, Mayo G, Price P, FitzGerald GA (1991) Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137–1141
Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thromboasthenic-like state in normal platelets and binds to glycoprotein IIb and/ or IIIa. J Clin Invest 72:325–338
De Witt DL, Smith WL (1988) Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85:1412–1416 (Erratum: Proc Natl Acad Sci USA 85:5056, 1988)
Di Minno G, Cerbone AM, Mattioli PM, Turco S, Iovine C, Mancini M (1985) Functionally thromboasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 75:328–338
Diener H, Cuhla L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurolog Sci 143:1–13
Doolittle RF, Watt KWK, Cottrell BA et al. (1979) The aminoacid sequence of the α chain of human fibrinogen. Nature 280:464–468
D’Souza SE, Ginsberg MH, Plow EF (1991) Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 16:246–250
Dunn FW, Soria J, Soria C, Thomaidis A, Lee H, Caen JP (1984) In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen on platelets. Agents Actions 15:97–103
Ferguson JJ, McDonough TJ, Worley SJ et al. (1996) Clinical outcome of “high-risk” vs “elective” patients undergoing percutaneous coronary intervention: results from IMPACT II. J Am Coll Cardiol 27:180A
Fitzgerald DJ, Catella F, FitzGerald GA (1986) Platelet activation in unstable coronary disease. N Engl J Med 315:983–989
Fitzgerald DJ, Fragetta J, FitzGerald GA (1988) Prostaglandin endoperoxide modulate the response to thromboxane synthase inhibition during coronary thrombosis. J Clin Invest 82:1708–1713
FitzGerald GA, Brash AR, Oates JA, Pedersen AK (1983) Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 71:1336–1343
FitzGerald GA, Reilly IA, Pedersen AK (1985) The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 72:1194–1201
FitzGerald GA (1987) Modern drug therapy: dipyridamole. N Engl J Med 316:1247–1257
FitzGerald GA (1990) Ticlopidine in unstable angina. A more expensive aspirin? Circulation 82:296–298
FitzGerald GA (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68:11B–15B
FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Brash AR (1993) Endogenous prostacyclin biosynthesis and platelet function during chronic aspirin administration in man. J Clin Invest 71:676–688
Fox JE (1993) The platelet cytoskeleton. Thromb Haemost 70:884–893
Funk CD, Funk LB, Kennedy ME, Pong AS, FitzGerald GA (1991) Human platelet/erithroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, mutagenesis and gene chromosomal assignment. Faseb J 5:2304–2312
Gawaz M, Neumann FJ, Ott I, May A, Schömig A (1996) Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 94:279–285
Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AGG, and the CATS Group (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 6:1215–1220
Ginsberg MH, Frelinger AL, Lam SCT, Forsyth J, McMillan R, Plow EF, Shattil SJ (1990) Analysis of platelet aggregation disorders based on flow cytometric analysis of platelet membrane glycoprotein IIb/IIIa with conformation specific monoclonal antibodies. Blood 76:2017–2023
Ginsberg MH, Du X, Plow EF (1992) Inside-out integrin signalling. Curr Opin Cell Biol 4:766–771
Gogstad GO, Brosstad F, Krutnes MB, Hagen I, Solum NO (1982) Fibrinogen binding properties of the human platelet glycoprotein IIb/IIIa complex: a study using crossed-radioimmunoelectophoresis. Blood 60:663–671
Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J (1987) Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 80:1435–1445
Grotta J (1993) Is aspirin effective in preventing strokes in diabetic patients? Stroke 24:760
Hall P, Nakamura S, Maiello L, Itok A, Blengino S, Martini G, Ferraro M, Colombo A (1996) A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 93:215–222
Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2294–2298
Harbison JW, for the Ticlopidine Aspirin Stroke Study Group (1992) Ticlopidine versus aspirin for the prevention of recurrent stroke: analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 23: 1723–1727
Hla T, Neilson K (1992) Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 89:7384–7388
Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B, and the Ticlopidine Aspirin Stroke Study Group (1989) A randomized trial comparing ticlopidine hydrocloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321:501–507
Herbert JM, Frehel D, Vallee E, Keffer G, Gouy D, Berger Y, Defreyn G, Maffrand JP (1993) Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11:180–198
Hoet B, Falcon C, De Reys S, Arnout J, Deckmyn H, Vermylen J (1990) R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 75:646–653
Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ (1993) Transdermal modification of platelet function: a dermal aspirin preparation selectively inhibits paltelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 88:556–561
Kereiakes DJ, Runyon JP, Kleiman NS et al. (1996) Differential dose-response to oral Xemilofiban after antecedent intravenous Abciximab administration for complex coronary intervention. Circulation 94:906–910
King SB, Willerson JT, Ross AM, Herrmann HC, Lipschutz KH, and the RESTORE Investigators (1996) Time course of reduction in adverse cardiac events following angioplasty using a IIb/IIIa receptor blocker, tirofiban: The restore trial. Circulation 94:1155A
Kopp E, Ghosh S (1994) Inhibition of NF-kB by sodium salicylate and aspirin. Science 265:956–959
Kloczewiak M, Timmons S, Lukas TJ, Hawiger J (1984) Platelet receptor recognition site on human fibrinogen: synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 23:1767–1774
Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS-10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866–12872
Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271:927–934
Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chelser E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309:396–403
Maffrand JP, Defreyn G, Bernat A, Delebasse D, Tissinier AM (1988) Reviewed pharmacology of ticlopidine. Angiology 77:6–13
Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ (1980) Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 66:979–986
Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91:3228–3232
McAdam B, Keimowtz RM, Maher M, Fitzgerald DJ (1996) Transdermal modification of platelet function: an aspirin patch system results im marked suppression of platelet cyclooxygenase. J Pharmacol Exp Therap 277:559–564
McAdam BV, FitzGerald GA (1997) Enzymatic regulation of the prostaglandin response in a human model of inflammation. In: Bazan N, Vane JR (eds) New targets in inflammation. Kluwer, Lancaster
McEver RP (1990) The clinical significance of platelet membrane glycoproteins. Hematol Oncol Clin North Am 4:87–103
Mills DCB, Puri R, Hu CJ, Minniti C, Grana C, Freedman MD, Colman RF, Colman RW (1992) Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscl Thrombosis 12:430–436
Mitchell JA, AKarasereenont P, Thiemermann C, Flower RJ, Vane JR (1994) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693–11697
Muller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G, Eisert WG (1990) Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 30:179–186
Muller TH, Weisenberger H, Brickl R, Kirchner M, Narjes H, Himmelsbach F, Guth B, Krause J (1995) Pharmaco-dynamics and kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist and its orally active prodrug BIBU 104 in man. Thromb Haem 73:2081A
Nichols AJ, Ruffolo RR, Huffman WF, Poste G, Samanen J (1992) Development of Gp IIb/IIIa antagonists as antithrombotic drugs. Trends Pharmacol Sci 13:413–417
Nowak J, FitzGerald GA (1989) Redirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in man. J Clin Invest 83:380–385
Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ, for the IMPACT-AMI Investigators (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation (in press)
Paragon Investigators (1996) A randomized trial of potent platelet IIb/IIIa antagonism, heparin or both in patients with unstable angina. The PARAGON study. Circulation 94:3234A
Parise LV, Phillips DR (1985) Reconstitution of the purified platelet fibrinogen receptor: fibrinogen binding properties of the glycoprotein IIb/IIIa complex. J Biol Chem 260:10698–10707
Parise LV, Helgerson SL, Steiner B, Nannizzi L, Phillips DR (1987) Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb/IIIa. J Biol Chem 262:12597–12602
Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366–1372
Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Creminon C, Maclouf J, Patrono C (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exper Therap 271:1705–1712
Pedersen AK, FitzGerald GA (1984) Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311:1206–1211
Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R (1988) Randomised trial of prophy lactic daily aspirin in British male doctors. Brit Med 296:313–316
Phillips DR, Charo IF, Scarborough RM (1991) Gp IIb/IIIa: the responsive integrin. Cell 65:359–362
Plow EF, Ginsberg MH (1989) GpIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 9:117–156
Resar JR, Brinker JA, Gerstenblith G, Blumenthal RS, Dudek A, Coombs VJ, Goldschmidt-Clermont PJ (1996) Disparity of Integrilin inhibition of platelet aggregation and GP IIb/IIIa fibrinogen binding in angioplasty patients. Circulation 94:567A
Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB (1994) Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arteriosclerosis Thrombosis 14:1021–1031
Roth GJ, Majerus PW (1975) The mechanism of the effect of aspirin on platelets. Acetylation of a particular fraction protein. J Clin Invest 56:624–632
Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 72:3073–3076
Ruoshlati E, Pierschbacher MD (1986) Arg-Gly-Asp: a versatile cell recognition signal. Cell 44:517–518
Savage MP, Goldberg S, Bove A et al., for the M-HEART II Study Group (1995) Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 92:3194–3200
Savi P, Laplace MC, Maffrand JP, Herbert JM (1994) Binding of 3H-2-Methylthio ADP to rat platelets. Effect of Clopidogrel and ticlopidine. J Pharmacol Exp Ther 269:772–777
Scarborough RM, Rose JW, Hsu MA et al. (1991) Barbourin: a GpIIb/IIIa-specific integrin antagonist from the venom of Sisturus m. barbouri. J Biol Chem 266:9359–9362
Schafer AI, Crawford DD, Gimbrone MA (1984) Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 73:1105–1112
Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR (1988) Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 318:1714–1719
Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J, for the CARPORT Study Group (1991) Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Circulation 84:1568–1580
Shattil SJ, Hoxie JA, Cunningham M, Brass LF (1985) Changes in the platelet membrane glycoprotein IIb/IIIa comples during platelet activation. J Biol Chem 260:11107–11114
Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Kass R, Blanche C, Matloff J, Morgenstern et al. (1986) Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315:913–919
Simoons ML, de Boer JM, van den Brand MJBM, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF et al. (1994) Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 89:596–603
Simpfenndorfer C, Kottke-Marchant Kandice, Topol E (1996) First experience with chronic platelet Gp IIb/IIIa receptor blockade: A pilot study of xemilofiban, an orally active antagonist, in unstable angina patients eligible for PTCA. J Am Coll Cardiol 27:242A
Smith WL (1992) Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263:F181–F191
Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 321:129–135
Tcheng JE, Harrington RA, Kottke-Marchant K et al. (1995a) Multicenter randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 91:2151–2157
Tcheng JE, Lincoff M, Sigmon KN et al. (1995b) Platelet glycoprotein IIb/IIIa inhibition with Integrelin during percutaneous coronary intervention: The IMPACT II Trial. Circulation 92:2595A
Tcheng JE (1996) Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am J Cardiol 78:35–40
The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956–961
The RAPT Investigators (1994) Randomized trial of Ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus aspirin patency trial (RAPT). Circulation 89:588–595
Théroux P, Latour JG, Leger-Gauthier C, De Lara J (1987) Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 75:156–162
Théroux P, Kouz S, Roy L et al., on behalf of the Investigators (1996) Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 94:899–905
Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, The EPIC Investigators (1994) Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 343:881–886
Van de Werf F (1996) More evidence for a beneficial effect of platelet glycoprotein IIb/ IIIa blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur Heart J 17:325–326
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232–235
van Gijn J, Algra A (1994) Ticlopidine: trials and torture. Stroke 25:1097–1098
Weber C, Erl W, Pietsch A, Weber PC (1995) Aspirin inhibits nuclear factor-kB mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 91:1914–1917
Weisberg LA (1993) The efficacy and safety of ticlopidin and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. Neurology 43:27–31
Weiss E, Bray PF, Tayback M, Schulman SP, Kickler TS, Becher LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ (1996) A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090–1094
Yao SK, Ober JC, Ferguson JJ, Andersson HV, Maraganore J, Buja LM, Willerson JT (1992a) Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 86:1993–1999
Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM, Willerson JT (1992b) ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 70:39–48
Yao SK, Ober JC, Ferguson JJ, Maffreand JP, Anderson HV, Buja LM, Willerson JT (1994) Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 267:H488–H493
Yokoyama C, Tanabe T (1989) Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Comm 165:888–894
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Catella-Lawson, F., FitzGerald, G.A. (1997). Therapeutic Aspects of Platelet Pharmacology. In: von Bruchhausen, F., Walter, U. (eds) Platelets and Their Factors. Handbook of Experimental Pharmacology, vol 126. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60639-7_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-60639-7_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64488-7
Online ISBN: 978-3-642-60639-7
eBook Packages: Springer Book Archive